| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8674228 | Molecular Metabolism | 2018 | 38 Pages |
Abstract
Our findings establish that specific targeting of hepatic PDKs with the PDK inhibitor PS10 is an effective therapeutic approach to maintaining glucose and lipid homeostasis in obesity and T2D, without the harmful ketoacidosis associated with systemic inhibition of PDKs.
Related Topics
Life Sciences
Neuroscience
Endocrine and Autonomic Systems
Authors
Cheng-Yang Wu, Shih-Chia Tso, Jacinta L. Chuang, Wen-Jun Gui, Mingliang Lou, Gaurav Sharma, Chalermchai Khemtong, Xiangbing Qi, R. Max Wynn, David T. Chuang,